(MedPage Today) — SAN FRANCISCO — The response rate in metastatic gastroesophageal cancer improved by a relative 50% when patients received experimental activated T cells in addition to standard therapy, according to a small phase II study…
Source link : https://www.medpagetoday.com/meetingcoverage/mgics/119390
Author :
Publish date : 2026-01-12 20:32:00
Copyright for syndicated content belongs to the linked Source.













